SCHEMBL753491

SCHEMBL753491

Cc1nc(N)cc(-c2c(Nc3ccc(NC(=O)N4CCOC(C)C4)cc3)nc3ccccn23)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 10/20 0.49
MTOR P42345 10/20 0.49
RXFP1 Q9HBX9 1/20 0.35
HPGD P15428 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NAMPT P43490 1/20 0.34
ALDH1A1 P00352 3/20 0.34
GLA P06280 2/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
CCNE1 P24864 2/20 0.34
CDK2 P24941 2/20 0.34
USP7 Q93009 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755278 0.89 PIK3CA (0.53) PIK3CAMTORHPGDSMN1; SMN2GAA
SCHEMBL764269 0.87 MTOR (0.50) PIK3CAMTOR
SCHEMBL755273 0.85 PIK3CA (0.54) PIK3CAMTORSMN1; SMN2MAPTNAMPT
SCHEMBL11033572 0.83 PIK3CA (0.49) PIK3CAMTORHPGDSMN1; SMN2GAA
SCHEMBL2786863 0.83 PIK3CA (0.51) PIK3CAMTORNAMPTGLACCNE1
SCHEMBL2787772 0.82 PIK3CA (0.51) PIK3CAMTORRXFP1HPGDSMN1; SMN2
SCHEMBL2790005 0.80 PIK3CA (0.62) PIK3CAMTORHPGDNPSR1ALDH1A1
SCHEMBL11028397 0.79 PIK3CA (0.59) PIK3CAMTORGLACCNE1CDK2
SCHEMBL11032907 0.79 PIK3CA (0.54) PIK3CAMTORHPGDGAAMAPT
SCHEMBL2771022 0.78 PIK3CA (0.62) PIK3CAMTORSMN1; SMN2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885RXFP1 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.